Curasan AG reported consolidated earnings results for the third quarter and nine months of 2016. For the nine months, the company's adjusted gross revenues rose by 8.9% over the comparable period in 2015 to EUR 4.83 million. For the nine months, earnings before interest, taxes, depreciation and amortization (EBITDA), which was clearly positive in the previous year due to the settlement with Stryker, was within expectations at negative EUR 1.64 million against EUR 3.09 million a year ago.

Despite significantly higher costs due to scheduled increases in expenditures for marketing and sales, the company succeeded in cutting the losses in the third quarter compared to the previous year. The quarterly loss was EUR 0.84 million against EUR 0.87 million a year ago.

Based on the sales already invoiced in the fourth quarter and the expected year-end business, the management board of the company currently assumes gross revenues of EUR 6.7 million to EUR 7.1 million expected for the full year will be fulfilled in the mid- to upper range.